Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
Protecting Patient Access to Cancer and Complex Therapies Act
Client: PFIZER INC. · Firm: PFIZER INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2026 · third_quarter · Q3
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
Source: Senate LDA
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
Client: PFIZER INC. · Firm: PFIZER INC.
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
H.R. 4101 - Cancer Drug Parity Act of 2025 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program Section 301 Investigation re: Germany Issues FDA User Fee Agreements: 2027 PDUFA Cycle 340B Program Reform Prior Authorization Vaccine Access and Coverage FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Pandemic and All-Hazards Preparedness Act (PAHPA)
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PFIZER INC. · Firm: PFIZER INC.
H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PFIZER INC. · Firm: PFIZER INC.
H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 VICP Reform and Excise Tax Tax Cuts and Jobs Act (TCJA) Comprehensive Corporate Tax Reform
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PFIZER INC. · Firm: PFIZER INC.
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Prescription Drug Transparency and Affordability Act
Client: PFIZER INC. · Firm: PFIZER INC.
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
National Defense Authorization Act for Fiscal Year 2026
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
National Defense Authorization Act for Fiscal Year 2026
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
National Defense Authorization Act for Fiscal Year 2026
Client: PFIZER INC. · Firm: PFIZER INC.
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2026 · first_quarter · 1A
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
2026 · second_quarter · Q2
H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues
Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2026 · first_quarter · Q1
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
2025 · fourth_quarter · 4A
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
Filing targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
2025 · third_quarter · 3A
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2025 · fourth_quarter · 4A
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
2025 · third_quarter · 3A
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2025 · fourth_quarter · Q4
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
2025 · second_quarter · 2A
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
2025 · third_quarter · Q3
Vaccine Policy, Coverage and Access HR 4317 - PMB Reform Act of 2025 Gavi Vaccines Alliance Issues HR 2214 - DRUG Act S 832 - EPIC Act of 2025 S 864 - HELP Copays ACT S 882 - Patients Before Middlemen Act Prescription Drug-Use-Related Software (PDURS): Digital Medicine Lyme Disease Issues Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients IRA Biosimilars Pause Fix, Biosimilar Legislation H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause Vaccine Coverage and Access Drug Pricing
International Supply Chain Global Access Most Favored Nation Policies Tariffs Non-Tariff Trade Barriers United States-Mexico-Canada Agreement (USMCA)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2025 · second_quarter · 2A
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
2025 · second_quarter · Q2
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
2025 · first_quarter · Q1
H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs
2024 · fourth_quarter · 4A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
2024 · first_quarter · 1A
PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR5378 - Lower Costs More Transparency Act Inflation Reduction Act /Medicare Price Setting 340B Reform Cell and Gene Therapy Access Model HR1458 - Access to Prescription Digital Therapeutics Act of 2023
Pandemic Preparedness/PAHPA Drug Pricing/Inflation Reduction Act: HR7174; Medicare Price Setting
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2024 · fourth_quarter · 4A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
2024 · fourth_quarter · 4A
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
2024 · fourth_quarter · 4A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
2024 · fourth_quarter · Q4
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax Vaccine Injury Compensation Fund VICP Transition Comprehensive Federal Tax Reform
2024 · third_quarter · 3A
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax VICP Transition Comprehensive Federal Tax Reform
VICP Reform and Excise Tax Inflation Reduction Act (IRA) HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Part D Payer Utilization Management Drug Shortages S2916 - Prescription Information Modernization Act of 2023 Vaccines, Clinical Trials and Coverage S2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability HR 2666 - Medicaid Value Based Payments for Patients (MVP) Act HR 4758 - Accelerating Kids Access to Care Act HR 7384 - Rare Pediatric Disease Priority Review (PRV) Voucher Trade-Related Aspects of Intellectual Property Rights March-in Framework Guidance and Policies S.79 - Interagency Patent Coordination and Improvement Act of 2023 S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.150 - Affordable Prescriptions for Patients Act of 2023 S.2780 - Medication Affordability and Patent Integrity Act Digital: Data Flows and Digital Trade
2024 · third_quarter · Q3
Comprehensive Corporate Tax Reform Tax Cuts and Jobs Act (TCJA) VICP Reform and Excise Tax VICP Transition Comprehensive Federal Tax Reform
VICP Reform and Excise Tax Inflation Reduction Act (IRA) HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Part D Payer Utilization Management Drug Shortages S2916 - Prescription Information Modernization Act of 2023 Vaccines, Clinical Trials and Coverage S2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability HR 2666 - Medicaid Value Based Payments for Patients (MVP) Act HR 4758 - Accelerating Kids Access to Care Act HR 7384 - Rare Pediatric Disease Priority Review (PRV) Voucher Trade-Related Aspects of Intellectual Property Rights March-in Framework Guidance and Policies S.79 - Interagency Patent Coordination and Improvement Act of 2023 S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.150 - Affordable Prescriptions for Patients Act of 2023 S.2780 - Medication Affordability and Patent Integrity Act Digital: Data Flows and Digital Trade
2024 · second_quarter · Q2
VICP Reform and Excise Tax, VICP Transition Inflation Reduction Act (IRA)/Medicare Price Setting HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Antimicrobial Resistance (AMR) Policy S.2305 - Biosimilar Red Tape Elimination Act Biosimilar Access and Interchangeability IRA Mitigation H.R. 4925 - EPIC Act
Comprehensive Corporate Tax Reform VICP Reform and Excise Tax, VICP Transition
PBM Transparency and Reform: S1375/HR830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act HR8816 - American Medical Innovation and Investment Act of 2024
2024 · first_quarter · Q1
PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act S2973 - Modernizing and Ensuring PBM Accountability Act S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act HR5378 - Lower Costs More Transparency Act Inflation Reduction Act /Medicare Price Setting 340B Reform Cell and Gene Therapy Access Model HR1458 - Access to Prescription Digital Therapeutics Act of 2023
Pandemic Preparedness/PAHPA Drug Pricing/Inflation Reduction Act: HR7174; Medicare Price Setting
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2023 · fourth_quarter · Q4
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
Medicare Part D Rebate Reform- PBMs Out-Of-Pocket Costs Government Negotiation on Medicare Antimicrobial Resistance March-In
TRIPS Waiver Bayh-Dole March-in-Rights General IP Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2023 · third_quarter · Q3
TRIPS Waiver Bayh-Dole March-in-Rights General IP Issues
Medicare Part D Rebate Reform- PBMs Out-Of-Pocket Costs Government negotiation on Medicare Antimicrobial Resistance March-In
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2023 · second_quarter · Q2
Medicare Part D Rebate Reform- PBMs Out-Of-Pocket Costs Government negotiation on Medicare Antimicrobial Resistance March-In
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
TRIPS Waiver Bayh-Dole March-in-Rights General IP Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2023 · first_quarter · Q1
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/ Excise Tax PDUFA Pandemic Preparedness/PAHPA
TRIPS Waiver Bayh-Dole Marc-in-Rights General IP Issues
Medicare Part D Rebate Reform- PMBs Out-Of-Pocket Costs Government negotiation on Medicare Antimicrobial Resistance March-In
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · second_quarter · 2A
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act Minimum Tax
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
2022 · first_quarter · 1A
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
2022 · fourth_quarter · Q4
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2022 · third_quarter · Q3
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
2022 · second_quarter · 2A
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act Minimum Tax
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
2022 · first_quarter · 1A
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax Antimicrobial Resistance/HR 3932 COVID Relief Package/Appropriations PDUFA
2022 · second_quarter · Q2
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act Minimum Tax
2022 · first_quarter · Q1
TRIPS Waiver General IP Issues Bayh-Dole March-In Rights
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax Antimicrobial Resistance/HR 3932 COVID Relief Package/Appropriations PDUFA
2021 · first_quarter · 1A
Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation
TRIPS Waiver
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Price Transparency International Reference Pricing/Most Favored Nations
2021 · fourth_quarter · Q4
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation Manufacturing Credits
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Antimicrobial Resistance
2021 · third_quarter · Q3
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Antimicrobial Resistance
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation Manufacturing Credits
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · second_quarter · Q2
Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Antimicrobial Resistance
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs International Reference Pricing/Most Favored Nations
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation Manufacturing Credits
2021 · first_quarter · Q1
Drug Pricing Biosimilars Drug Shortages Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Price Transparency International Reference Pricing/Most Favored Nations
TRIPS Waiver
2020 · fourth_quarter · Q4
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Price Transparency International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Rebate Reform Vaccine Infrastructure Drug Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · third_quarter · Q3
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency International Reference Pricing/Most Favored Nations
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform Vaccine Infrastructure Drug Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · second_quarter · Q2
U.S.- Japan Trade Negotiations Foreign Market Access Issues NAFTA/USMCA International Supply Chain/Buy America U.S.- U.K. Trade Negotiations U.S. - Kenya FTA
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform Vaccine Infrastructure
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2020 · first_quarter · Q1
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · fourth_quarter · 4A
Health Extenders/Congressional Appropriations
U.S.- Japan Trade Negotiations China Trade Negotiations NAFTA/USMCA Foreign Market Access Issues
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
2019 · fourth_quarter · Q4
U.S.- Japan Trade Negotiations China Trade Negotiations NAFTA/USMCA Foreign Market Access Issues
Creates Act Patent Thickets/Hopping
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
2019 · third_quarter · Q3
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · second_quarter · Q2
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements Price Transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · first_quarter · 1A
Creates Act
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2019 · first_quarter · Q1
Medicare Part D Coverage Gap Rebate Reform Out of Pocket Costs Value Based Arrangements
Creates Act
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · fourth_quarter · 4A
Drug Pricing Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Medicare Part D Coverage Gap
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · third_quarter · 3A
2018 FDA & Labor/HHS Appropriation Bills Bipartisan Budget Act of 2018
Creates Act Transferable exclusivity
Medicare Part D Coverage Gap
2018 · fourth_quarter · Q4
Drug Pricing Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Medicare Part D Coverage Gap
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · third_quarter · Q3
Drug Pricing Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Creates Act Transferable exclusivity
Medicare Part D Coverage Gap
2018 · first_quarter · Q1
Medicare Part D Coverage Gap Biosimilar pass-through
Drug Pricing Biosimilars Reimbursement Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease
2018 FDA & Labor/HHS Appropriation Bills Bipartisan Budget Act of 2018 Omnibus Appropriations Act of 2018
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · first_quarter · RA
Healthcare and access issues/IP Protection/Trade
Healthcare and access issues/IP Protection/Trade
Healthcare and access issues/IP Protection/Trade
2017 · third_quarter · 3A
Drug Pricing User Fees Biosimilars Reimbursement Antibiotic Resistance Drug Shortages Reimbursement for products treating Sickle Cell Disease
Medicare Rebates/Medicare Part D/C Medicare Part B CMMI Demo Non-Interference Re-Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · fourth_quarter · Q4
Comprehensive Tax Reform Territorial Systems Border Adjustability Tax
Drug Pricing Biosimilars Reimbursement Antibiotic Resistance Drug Shortages Reimbursement for products treating Sickle Cell Disease
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · third_quarter · Q3
Medicare Rebates/Medicare Part D/C Medicare Part B CMMI Demo Non-Interference Re-Importation
Drug Pricing User Fees Biosimilars Reimbursement Antibiotic Resistance Drug Shortages Reimbursement for products treating Sickle Cell Disease
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · first_quarter · 1A
Omnibus Appropriations Bill 2018 FDA & Labor/HHS Appropriation Bills
Medicare Rebates/Medicare Part D Medicare Part B CMMI Demo Non-Interference Re-Importation
Drug Pricing User Fees Biosimilars Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · second_quarter · Q2
Medicare Rebates/Medicare Part D Medicare Part B CMMI Demo Non-Interference Re-Importation Part A Reimbursement
2018 FDA & Labor/HHS Appropriation Bills
Drug Pricing User Fees Biosimilars Reimbursement Antibiotic Resistance
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2017 · first_quarter · Q1
Omnibus Appropriations Bill 2018 FDA & Labor/HHS Appropriation Bills
Drug Pricing User Fees Biosimilars Reimbursement
Medicare Rebates/Medicare Part D Medicare Part B CMMI Demo Non-Interference Re-Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2016 · fourth_quarter · 4A
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo Re-importation
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy User Fees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2016 · third_quarter · 3A
Omnibus Appropriations Bill 2017 FDA & Labor/HHS Appropriation Bills
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2016 · second_quarter · 2A
Deferral Comprehensive Tax Reform Territorial Systems Patent Innovation Box Cadillac Tax Inversions Section 385 Proposed Regulations
Omnibus Appropriations Bill LHHA Appropriations 2017 FDA & Labor/HHS Appropriation Bills
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo
2016 · fourth_quarter · Q4
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo Re-importation
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy User Fees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2016 · second_quarter · 2A
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Canada IP/Trade Issues South Africa IP Issues China IP Saudia Arabia Pricing Issues United Nations Health Panel Thermacare EU Privacy Shield G7/G20 APEC OECD
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
2016 · third_quarter · Q3
Omnibus Appropriations Bill 2017 FDA & Labor/HHS Appropriation Bills
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2016 · second_quarter · Q2
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B CMMI Demo
Omnibus Appropriations Bill LHHA Appropriations 2017 FDA & Labor/HHS Appropriation Bills
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
2016 · first_quarter · Q1
Deferral Comprehensive Tax Reform Territorial Systems Patent Innovation Box Cadillac Tax Inversions
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
Medicare Rebates/Medicare Part D Non-Interference Medicare Part B Reimbursement Medicare Part B Demonstration Proposal Medicare Part B CMMI Demo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2015 · fourth_quarter · Q4
Deferral Comprehensive Tax Reform Territorial Systems Tax Extenders Patent Innovation Box Cadillac Tax Inversions
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues China IP Saudia Arabia Pricing Issues WTO Trade Facilitation Agreement (TFA) Trade Adjustment Assistance United Nations Health Panel
Omnibus Appropriations Bill
2015 · third_quarter · 3A
FDA Funding 340B 21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
Patent Troll Legislation
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues China IP Saudia Arabia Pricing Issues WTO Trade Facilitation Agreement (TFA) Trade Adjustment Assistance
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2015 · second_quarter · 2A
Deferral Comprehensive Tax Reform Territorial Systems Tax Extenders Patent Innovation Box
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues China IP Algeria Pricing Issues Saudia Arabia Pricing Issues WTO Trade Facilitation Agreement (TFA) Vietnam Distribution Trade Adjustment Assistance
FDA Funding HHS Appropriations 340B Antibiotics Dormant Therapies FDA Breakthrough Therapies 21st Century Cures Initiative Senate Innovation Project
2015 · second_quarter · Q2
Patent Troll Legislation
FDA Funding HHS Appropriations 340B Antibiotics Dormant Therapies FDA Breakthrough Therapies 21st Century Cures Initiative Senate Innovation Project
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues China IP Algeria Pricing Issues Saudia Arabia Pricing Issues WTO Trade Facilitation Agreement (TFA) Vietnam Distribution Trade Adjustment Assistance
2015 · first_quarter · Q1
Medicare Rebates/Medicare Part D Non-Interference SGR "Fix" Negotiations
Deferral Comprehensive Tax Reform Territorial Systems Tax Extenders Patent Innovation Box
Patent Troll Legislation
2014 · third_quarter · Q3
Deferral Comprehensive Tax Reform Territorial Systems BudgetBase Erosion and Profit Shifting (BEPS)
Health Care Reform FDA Funding Prescription Drug User Fee Act (PDUFA) Implementation HHS AppropriationsInterior Appropriations 340B
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference SGR "Fix" Negotiations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2014 · fourth_quarter · Q4
Health Care Reform FDA Appropriations HHS Appropriations Interior Appropriations 340B Antibiotics/Dormant Therapies Domestic Drug Pricing - General FDA Breakthrough Therapies 21st Century Cures Initiative
Medicare Rebates/Medicare Part D Non- Interference SGR "Fix" Negotiations CMS Medicare Manual Changes
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues China IP Saudia Arabia IP Taiwan Pricing Issues Algeria Pricing Issues Venezuela Pricing Issues WTO Trade Facilitation Agreement (TFA) APEC Leaders Meeting
2014 · third_quarter · Q3
Deferral Comprehensive Tax Reform Territorial Systems BudgetBase Erosion and Profit Shifting (BEPS)
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference SGR "Fix" Negotiations
Health Care Reform FDA Funding Prescription Drug User Fee Act (PDUFA) Implementation HHS AppropriationsInterior Appropriations 340B
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2014 · second_quarter · Q2
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference SGR "Fix" Negotiations
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP)Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues Korea IP/Trade Issues China IP Saudia Arabia IP Turkey Pricing/IP
Health Care Reform FDA Funding Prescription Drug User Fee Act (PDUFA) Implementation HHS AppropriationsInterior Appropriations
2014 · first_quarter · Q1
Patent Settlements Patent Troll Legislation CMS Rule Preventing Abuse of Cough Treatment Act
Health Care Reform FDA Funding Prescription Drug User Fee Act (PDUFA) Implementation Budget Control Act/Sequester User FeesHHS Appropriations Interior Appropriations
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference SGR "Fix" Negotiations
2013 · third_quarter · 3A
Certified Importer Program Supply Chain Issues
Patent Settlements Patent Reform Patent Troll Legislation
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP)Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues Korea IP/Trade Issues
2013 · second_quarter · 2A
Patent Settlements Patent Reform Patent Troll Legislation
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Certified Importer Program Supply Chain Issues
2013 · first_quarter · 1A
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Patent Settlements
Health Care Reform FDA Funding Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer ProgramDeficit Reduction/Joint Select Committee Issues (Budget Control Act) S. 3817, Food and Drug Administration Safety and Innovation Act
2013 · third_quarter · RA
Health care implementation Patent protection Consumer health issues
Health care implementation Patent protection Consumer health issues
Health care implementation Patent protection Consumer health issues
2013 · fourth_quarter · 4A
Patent Settlements Patent Troll Legislation
Health Care Reform FDA Funding Deficit Reduction/Joint Select Committee Issues (Budget Control Act) Prescription Drug User Fee Act (PDUFA) ImplementationSequester of User Fee
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP)Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues Korea IP/Trade Issues China IP Saudia Arabia IP Thailand Pricing Taiwan Pricing
2013 · third_quarter · 3A
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP)Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues Korea IP/Trade Issues
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Patent Settlements Patent Reform Patent Troll Legislation
2013 · second_quarter · 2A
Health Care Reform FDA Funding Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act)Prescription Drug User Fee Act (PDUFA) Implementation Sequester of User Fee Vaccines
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Patent Settlements Patent Reform Patent Troll Legislation
2013 · first_quarter · 1A
Health Care Reform FDA Funding Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer ProgramDeficit Reduction/Joint Select Committee Issues (Budget Control Act) S. 3817, Food and Drug Administration Safety and Innovation Act
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Patent Settlements
2013 · first_quarter · Q1
Certified Importer Program Supply Chain Issues
Patent Settlements
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
2013 · first_quarter · Q1
Certified Importer Program Supply Chain Issues
Patent Settlements
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
2012 · fourth_quarter · Q4
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation
H.R. 1406, Fairness to Pet Owners Act 2011 H.R. 1513, Great Ape Protection Act
Health Care Reform Prescription Drug User Fee Act (PDUFA) Antibiotic Incentives FDA Funding Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) S. 3817, Food and Drug Administration Safety and Innovation Act
2012 · third_quarter · Q3
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction PSE Issues Supply Chain Issues Counterfeits
Homeland Security and Defense Issues Surrounding Readiness for a Chemical Nerve Agent Attack or Industrial Accident.
Health Care Reform Prescription Drug User Fee Act (PDUFA) Antibiotic Incentives FDA Funding Antimicrobial Resistance Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) H.R. 2182, Generating Antibiotic Incentives Now Act of 2011 H.R. 452, Medicare Decisions Accountability Act S. 1734, Generating Antibiotic Incentives Now Act of 2011 S. 3817, Food and Drug Administration Safety and Innovation Act
2012 · second_quarter · Q2
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation
Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives FDA Funding Antimicrobial Resistance Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) House and Senate FY 2013 Labor HHS Appropriations H.R. 2182, Generating Antibiotic Incentives Now Act of 2011 H.R. 452, Medicare Decisions Accountability Act S. 1734, Generating Antibiotic Incentives Now Act of 2011 S. 668, Health Care Bureaucrats Elimination Act, 2011
2012 · first_quarter · 1A
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation
Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives FDA Funding Antimicrobial Resistance Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) House and Senate FY 2013 Labor HHS Appropriations H.R. 2182, Generating Antibiotic Incentives Now Act of 2011 H.R. 452, Medicare Decisions Accountability Act S. 1734, Generating Antibiotic Incentives Now Act of 2011 S. 668, Health Care Bureacrats Elimination Act, 2011
2012 · first_quarter · Q1
Counterfeit Pharmaceuticals Patent Settlements Stop Online Piracy Act
Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives FDA Funding Antimicrobial Resistance Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) House and Senate FY 2013 Labor HHS Appropriations H.R. 2182, Generating Antibiotic Incentives Now Act of 2011 H.R. 452, Medicare Decisions Accountability Act S. 1734, Generating Antibiotic Incentives Now Act of 2011 S. 668, Health Care Bureacrats Elimination Act, 2011
2011 · fourth_quarter · 4A
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits
Medicare Rebates/Medicare Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation
Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives Tax Extenders FDA Funding Antimicrobial Resistance Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) Vaccines (317 Program appropriations, Immunization Improvements Act) H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452, Medicare Decisions Accountability Act S. 1599, FY 2012 Labor HHS Appropriations Bill S. 668, Health Care Bureacrats Elimination Act, 2011
2011 · third_quarter · 3A
Medicare Prescription Drug Benefit Medicare Rebates/Medicare Part D Medicare Coverage Debt Ceiling and Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation H.R. 452, Medicare Decision Accountability Act, 2011 S. 1206, Medicare Drug Savings Act
Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Medicare Part D Antibiotic Incentives Tax Extenders Antimicrobial Resistance Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452, Medicare Decisions Accountability Act S. 668, Health Care Bureacrats Elimination Act, 2011 S. 1094, Combating Autism Act S. 1599, FY 2012 Labor HHS Appropriations Bill
2011 · second_quarter · 2A
Health Care Reform Comparative Effectiveness Research Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives Tax Extenders Antimicrobial Resistance Strategies to Address Antimicrobial Resistance Senate Labor - HHS Appropriations bill, with regard to funding of the 317 Program H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 S. 668, Health Care Bureacrats Elimination Act, 2011 S. 1094, Combating Autism Act
Medicare Prescription Drug Benefit Medicare Rebates Medicare Coverage Medicare Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation Debt Ceiling and Part D H.R. 452, Medicare Decision Accountability Act, 2011 S. 1206, Medicare Drug savings Act
2011 · first_quarter · 1A
Health Care Reform Comparative Effectiveness Research Prescription Drug User Fee Act (PDUFA) Follow on Biologics Medicare Part D Antibiotic Incentives Tax Extenders Antimicrobial Resistance Strategies to Address Antimicrobial Resistance H.R. 965 The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979 FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452 Medicare Decision Accountability Act, 2011 S. 668 Health Care Bureacrats Elimination Act, 2011
Importation The Food, Drug and Cosmetic Globalization Act Dextromethorphan Distribution Dextromethorphan Abuse Reduction H.R. 741 - Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373 - Fair Prescription Drug Competition Act, 2011
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
Filing targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
International Supply Chain Global Access Market Access Most Favored Nation Policies Tariffs Generics Foreign Freeriding Issues Non-Tariff Trade Barriers Trade Issues
Filing targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR)
VICP Reform and Excise Tax Vaccine Injury Compensation Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
VICP Reform and Excise Tax Vaccine Injury Compensation Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
VICP Reform and Excise Tax Vaccine Injury Compensation Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access
H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 VICP Reform and Excise Tax Tax Cuts and Jobs Act (TCJA) Comprehensive Corporate Tax Reform
HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
S723/HR1458 - Access to Prescription Digital Therapeutics Act HR8816 - American Medical Innovation and Investment Act of 2024 PBM Transparency and Reform S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
S723/HR1458 - Access to Prescription Digital Therapeutics Act HR8816 - American Medical Innovation and Investment Act of 2024 PBM Transparency and Reform S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Drug Pricing Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax Antimicrobial Resistance/HR 3932 COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act Minimum Tax
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Drug Pricing Support of Biosimilars Out-of-Pocket Costs Rebate Reform Vaccine Infrastructure/HR 3656 Excise Tax- S.3087 Antimicrobial Resistance/HR 3932/PASTEUR Act COVID Relief Package/Appropriations PDUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation U.S. Manufacturing Credits Build Back Better Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Medicare Part D support for access to treatments for obesity Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Medicare Part D Coverage Gap Rebate Reform Out-of-Pocket Costs Government Negotiation in Medicare
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation Manufacturing Credits
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Comprehensive Corporate Tax Reform International Tax Reform OECD Profit Allocation Manufacturing Credits
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Creates Act Patent Thickets/Hopping
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Health Extenders/Congressional Appropriations
Drug Pricing Biosimilars Drug Shortages Out of Pocket Costs Value Based Arrangements Rebate Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Drug Pricing Antibiotic Resistance/incentives Drug Shortages Reimbursement for products treating Sickle Cell Disease PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
2018 FDA & Labor/HHS Appropriation Bills Bipartisan Budget Act of 2018
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
Healthcare and access issues/IP Protection/Trade
Healthcare and access issues/IP Protection/Trade
Healthcare and access issues/IP Protection/Trade
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Canada IP/Trade Issues South Africa IP Issues China IP Saudia Arabia Pricing Issues United Nations Health Panel Thermacare EU Privacy Shield G7/G20 APEC OECD
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Omnibus Appropriations Bill LHHA Appropriations 2017 FDA & Labor/HHS Appropriation Bills
Deferral Comprehensive Tax Reform Territorial Systems Patent Innovation Box Cadillac Tax Inversions Section 385 Proposed Regulations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Deferral Comprehensive Tax Reform Territorial Systems Patent Innovation Box Cadillac Tax Inversions Section 385 Proposed Regulations
Trans Pacific Partnership Negotiations Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Canada IP/Trade Issues South Africa IP Issues China IP Saudia Arabia Pricing Issues United Nations Health Panel Thermacare EU Privacy Shield G7/G20 APEC OECD
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
21st Century Cures Initiative Senate Innovation Project Drug Pricing Biosimilars Reimbursement Policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Patent Troll Legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Deferral Comprehensive Tax Reform Territorial Systems Tax Extenders Patent Innovation Box
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP) Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues China IP Algeria Pricing Issues Venezuela Pricing Issues WTO Trade Facilitation Agreement (TFA) APEC Leaders Meeting Vietnam Distribution Israel Pricing
FDA Funding HHS Appropriations 340B Antibiotics Dormant Therapies FDA Breakthrough Therapies 21st Century Cures Initiative
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Deferral Excess Returns/Base Erosion Comprehensive Tax Reform Transition Rules for Comprehensive ReformTerritorial Systems Patent/Innovation Box Minimum Tax Taxation or Intangible Income Budget Base Erosion and Profit Shifting (BEPS)
Patent Settlements Patent Troll Legislation CMS Rule Preventing Abuse of Cough Treatment Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Trans Pacific Partnership Negotiations India IP/Trade Issues Miscellaneous Tariff Bill (MTB) Trans-Atlantic Trade & Investment Partnership (TTIP)Trade Promotion Authority/Fast-Track (TPA) Canada IP/Trade Issues South Africa IP Issues Korea IP/Trade Issues China IP Saudia Arabia IP Thailand Pricing Taiwan Pricing Turkey Pricing/IP
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Health Care Reform FDA Funding Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act)Prescription Drug User Fee Act (PDUFA) Implementation Sequester of User Fee Vaccines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Health Care Reform FDA Funding Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act)Prescription Drug User Fee Act (PDUFA) Implementation Sequester of User Fee Vaccines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Certified Importer Program Supply Chain Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Health care implementation Patent protection Consumer health issues
Health care implementation Patent protection Consumer health issues
Health care implementation Patent protection Consumer health issues
Certified Importer Program Supply Chain Issues
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation Non- Interference
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Certified Importer Program Supply Chain Issues
Health Care Reform FDA Funding Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act)Prescription Drug User Fee Act (PDUFA) Implementation Sequester of User Fee Vaccines
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Certified Importer Program Supply Chain Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Certified Importer Program Supply Chain Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Health Care Reform FDA Funding Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer ProgramDeficit Reduction/Joint Select Committee Issues (Budget Control Act) S. 3817, Food and Drug Administration Safety and Innovation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Health Care Reform FDA Funding Drug Shortages Homeland Security and Agriculture Appropriations Bill on Certified Importer ProgramDeficit Reduction/Joint Select Committee Issues (Budget Control Act) S. 3817, Food and Drug Administration Safety and Innovation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction PSE Issues Supply Chain Issues Counterfeits
Trans Pacific Partnership Negotiations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation
Trans Pacific Partnership Negotiations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits
Homeland Security and Defense Issues Surrounding Readiness for a Chemical Nerve Agent Attack or Industrial Accident.
Counterfeit Pharmaceuticals Patent Settlements Stop Online Piracy Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Counterfeit Pharmaceuticals Patent Settlements Stop Online Piracy Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits
Medicare Rebates/Medicare Part D Patient Protection and Affordable Care Act Implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Counterfeit Pharmaceuticals Patent Settlements Stop Online Piracy Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Counterfeit Pharmaceuticals Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S. 27, Preserve Access to Affordable Generics S.23, America Invents Act, 2011 H.R. 1249, America Invents Act, 2011
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011
Counterfeit Pharmaceuticals Expert Patent Courts Pilot Programs Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S. 27, Preserve Access to Affordable Generics S.23, America Invents Act, 2011 H.R. 1249, America Invents Act, 2011
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Counterfeit Pharmaceuticals Expert Patent Courts Pilot Programs Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S.23 - America Invents Act, 2011 S. 27 - Preserve Access to Affordable Generics H.R. 1249 - America Invents Act, 2011
Medicare Prescription Drug Benefit Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)